Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer

Y Song, MK Washington, HC Crawford - Cancer research, 2010 - AACR
Y Song, MK Washington, HC Crawford
Cancer research, 2010AACR
FOXA1 and FOXA2, members of the forkhead transcription factor family, are critical for
epithelial differentiation in many endoderm-derived organs, including the pancreas.
However, their role in tumor progression is largely unknown. Here, we identified FOXA1 and
FOXA2 as important antagonists of the epithelial-to-mesenchymal transition (EMT) in
pancreatic ductal adenocarcinoma (PDA) through their positive regulation of E-cadherin and
maintenance of the epithelial phenotype. In human PDA samples, FOXA1/2 are expressed …
Abstract
FOXA1 and FOXA2, members of the forkhead transcription factor family, are critical for epithelial differentiation in many endoderm-derived organs, including the pancreas. However, their role in tumor progression is largely unknown. Here, we identified FOXA1 and FOXA2 as important antagonists of the epithelial-to-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma (PDA) through their positive regulation of E-cadherin and maintenance of the epithelial phenotype. In human PDA samples, FOXA1/2 are expressed in all epithelia from normal to well-differentiated cancer cells, but are lost in undifferentiated cancer cells. In PDA cell lines, FOXA1/2 expression is consistently suppressed in experimental EMT models and RNAi silencing of FOXA1/2 alone is sufficient to induce EMT. Conversely, ectopic FOXA1/2 expression can potently neutralize several EMT-related E-cadherin repressive mechanisms. Finally, ectopic FOXA2 expression could reactivate E-cadherin expression in a PDA cell line with extensive promoter hypermethylation. In fact, demethylation-mediated reactivation of E-cadherin expression in these cells required concurrent reactivation of endogenous FOXA2 expression. We conclude that suppression of FOXA1/2 expression is both necessary and sufficient for EMT during PDA malignant progression. Cancer Res; 70(5); 2115–25
AACR